Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy [PDF]
Nicola Specchio, Nicola Pietrafusa, Marina Trivisano Rare and Complex Epilepsy Unit, Department of Neuroscience, Bambino Gesù Children’s Hospital, IRCCS, Rome, ItalyCorrespondence: Nicola SpecchioDepartment of Neuroscience, Bambino Ges ...
Specchio N, Pietrafusa N, Trivisano M
doaj +6 more sources
A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies. [PDF]
The Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, result from mutations in over a dozen genes. Although, adults are susceptible, the NCLs are frequently classified as pediatric neurodegenerative diseases due to their greater ...
Ryan D Geraets +7 more
doaj +7 more sources
Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa [PDF]
IntroductionThis study assessed the real-world effectiveness and safety of the enzyme replacement therapy (ERT), cerliponase alfa, to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease.MethodsData from the DEM-CHILD database were analyzed ...
Angela Schulz +11 more
doaj +6 more sources
Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis? [PDF]
AbstractNeuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare pediatric disorder associated with rapid neurodegeneration, and premature death in adolescence. An effective enzyme replacement therapy (cerliponase alfa) has been approved that can reduce this predictable neurological decline.
Nickel, Miriam +9 more
europepmc +7 more sources
Neurofilament light is a treatment‐responsive biomarker in CLN2 disease [PDF]
Objective Neuronal ceroid lipofuscinosis type 2 (CLN2 disease) is a rare, progressive, fatal neurodegenerative pediatric disorder resulting from deficiencies of the lysosomal enzyme tripeptidyl peptidase 1 that are caused by mutations in TPP1 ...
Yuanbin Ru +12 more
doaj +4 more sources
Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients [PDF]
Background CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1).
Sara E. Mole +20 more
doaj +7 more sources
Cerliponase Alfa for the Treatment of Atypical Phenotypes of CLN2 Disease: A Retrospective Case Series [PDF]
Background: The classic phenotype of CLN2 disease (neuronal ceroid lipofuscinosis type 2) typically manifests between ages 2 and 4 years with a predictable clinical course marked by epilepsy, language developmental delay, and rapid psychomotor decline.
Eva Wibbeler +15 more
europepmc +9 more sources
Evidence of the impact of CLN2 and CLN3 Batten disease on families in the United Kingdom [PDF]
Background Neuronal Ceroid Lipofuscinoses (NCLs), also known as Batten disease, are a group of inherited neurodegenerative disorders that mostly arise in childhood.
Sara E. Mole +14 more
doaj +18 more sources
GABAergic interneurons contribute to the fatal seizure phenotype of CLN2 disease mice [PDF]
The cellular etiology of seizures in CLN2 disease, a childhood-onset neurodegenerative lysosomal storage disorder caused by a deficiency of tripeptidyl peptidase 1 (TPP1), remains elusive.
Keigo Takahashi +13 more
doaj +6 more sources
Visual perception and macular integrity in non-classical CLN2 disease [PDF]
Abstract Purpose Patients with CLN2 suffer from epileptic seizures, rapid psychomotor decline and vision loss in early childhood. The aim of the study was to provide longitudinal ophthalmic data of patients with confirmed genetic mutation and non-classical disease course, marked by later onset, protracted progression and
Yevgeniya Atiskova +7 more
openaire +3 more sources

